Gauging by investor reaction you just might think that’s it’s all over for Dexcom (NASDAQ: DCXM). As we write shares are down some 33% and the trading day is not over yet. You just might get the impression that since Libre was approved by the FDA, that overnight Abbott (NYSE: ABT) became king of the CGM castle. Well you could think that but you would be wrong to do so.
First and we should not have to overstate what is obvious but Dexcom just got a lot cheaper and all of sudden a very attractive takeover candidate.
Second . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.